Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Multi-drug triplets often fail due to compounded toxicities that prevent complete dosing. Bispecific antibodies that hit two targets, such as VEGF and PD-1, may bypass delivery hurdles and create a tolerable backbone for future combination regimens.

Related Insights

The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.

Early 4-1BB agonists failed due to severe liver toxicity. Excalipoint's bispecifics solve this by requiring one arm to bind to a tumor before the other activates T-cells. This localizes the immune response, preventing systemic toxicity and reviving a previously failed mechanism for cancer therapy.

Unlike checkpoint inhibitors, the bispecific antibody Pazridamig (targeting HK2 and CD3) shows promising early signals in heavily pretreated prostate cancer. It demonstrated a low rate of side effects and convenient dosing, suggesting a viable new immunotherapeutic pathway.

Previously underperforming cancer targets like TIGIT and LAG-3 are seeing renewed interest. Innovative antibody engineering, such as creating bispecific antibodies that target multiple pathways simultaneously, is giving these 'failed' targets new life and potential for clinical success.

Beyond simply blocking the PD-1/PD-L1 pathway, these bispecifics may form a macromolecular structure with VEGF and PD-L1 in the tumor microenvironment. This structure can cause the cancer cell to internalize the PD-L1 protein, effectively removing it as a target and creating a dual blockade.

Bispecific antibodies targeting VEGF alongside PD-1 or PD-L1 combined with taxanes achieved 70% to 80% response rates in triple-negative breast cancer. Notably, these combinations demonstrated robust efficacy in PD-L1-negative patients, suggesting bispecific construct synergy overcomes VEGF-driven immunosuppression.

Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.

Bispecific antibodies, which target two antigens like PD-1 and VEGF simultaneously, are viewed as the next major upgrade to standard immunotherapy. Their 'cooperative binding' mechanism is expected to improve efficacy and safety, and early trial data suggest they could replace decade-old checkpoint inhibitors like pembrolizumab as the new standard of care.

Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.

The next wave in NSCLC immunotherapy involves bispecific antibodies, which are single molecules that simultaneously block both the PD-1/PD-L1 and VEGF pathways. Agents like Ivanesimab are showing superior progression-free survival compared to standard checkpoint inhibitors, establishing this dual-target approach as a leading area of development.

Bispecific Antibodies Offer a Tolerable Path to Target Multiple Oncologic Mechanisms Simultaneously | RiffOn